Literature DB >> 27365010

A framework for analysis of research risks and benefits to participants in standard of care pragmatic clinical trials.

Stephanie C Chen1, Scott Yh Kim2,3.   

Abstract

BACKGROUND/AIMS: Standard of care pragmatic clinical trials that compare treatments already in use could improve care and reduce costs, but there is considerable debate about the research risks of standard of care pragmatic clinical trials and how to apply informed consent regulations to such trials. We sought to develop a framework integrating the insights from opposing sides of the debate.
METHODS: We developed a formal risk-benefit analysis framework for standard of care pragmatic clinical trials and then applied it to key provisions of the US federal regulations.
RESULTS: Our formal framework for standard of care pragmatic clinical trial risk-benefit analysis takes into account three key considerations: the ex ante estimates of risks and benefits of the treatments to be compared in a standard of care pragmatic clinical trial, the allocation ratios of treatments inside and outside such a trial, and the significance of some participants receiving a different treatment inside a trial than outside the trial. The framework provides practical guidance on how the research ethics regulations on informed consent should be applied to standard of care pragmatic clinical trials.
CONCLUSION: Our proposed formal model makes explicit the relationship between the concepts used by opposing sides of the debate about the research risks of standard of care pragmatic clinical trials and can be used to clarify the implications for informed consent.
© The Author(s) 2016.

Entities:  

Keywords:  Comparative effectiveness randomized control trials; informed consent; pragmatic randomized control trials; research ethics; research risk analysis

Mesh:

Year:  2016        PMID: 27365010      PMCID: PMC5133165          DOI: 10.1177/1740774516656945

Source DB:  PubMed          Journal:  Clin Trials        ISSN: 1740-7745            Impact factor:   2.486


  27 in total

1.  Addressing low-risk comparative effectiveness research in proposed changes to US federal regulations governing research.

Authors:  Nancy Kass; Ruth Faden; Sean Tunis
Journal:  JAMA       Date:  2012-04-18       Impact factor: 56.272

2.  Long-term antimicrobial therapy in the prevention of recurrent soft-tissue infections.

Authors:  M Kremer; R Zuckerman; Z Avraham; R Raz
Journal:  J Infect       Date:  1991-01       Impact factor: 6.072

3.  Considerations in the evaluation and determination of minimal risk in pragmatic clinical trials.

Authors:  John D Lantos; David Wendler; Edward Septimus; Sarita Wahba; Rosemary Madigan; Geraldine Bliss
Journal:  Clin Trials       Date:  2015-09-15       Impact factor: 2.486

4.  OHRP and standard-of-care research.

Authors: 
Journal:  N Engl J Med       Date:  2014-11-12       Impact factor: 91.245

5.  The concept of risk in comparative-effectiveness research.

Authors:  John D Lantos; John A Spertus
Journal:  N Engl J Med       Date:  2014-11-12       Impact factor: 91.245

6.  Varieties of standard-of-care treatment randomized trials: ethical implications.

Authors:  Scott Y H Kim; Franklin G Miller
Journal:  JAMA       Date:  2015-03-03       Impact factor: 56.272

7.  Shorter dialysis times are associated with higher mortality among incident hemodialysis patients.

Authors:  Steven M Brunelli; Glenn M Chertow; Elizabeth D Ankers; Edmund G Lowrie; Ravi Thadhani
Journal:  Kidney Int       Date:  2010-01-20       Impact factor: 10.612

8.  Penicillin to prevent recurrent leg cellulitis.

Authors:  Kim S Thomas; Angela M Crook; Andrew J Nunn; Katharine A Foster; James M Mason; Joanne R Chalmers; Ibrahim S Nasr; Richard J Brindle; John English; Sarah K Meredith; Nicholas J Reynolds; David de Berker; Peter S Mortimer; Hywel C Williams
Journal:  N Engl J Med       Date:  2013-05-02       Impact factor: 91.245

9.  Antibiotic prophylaxis in recurrent erysipelas.

Authors:  A C Sjöblom; B Eriksson; C Jorup-Rönström; K Karkkonen; M Lindqvist
Journal:  Infection       Date:  1993 Nov-Dec       Impact factor: 3.553

10.  Shorter length dialysis sessions are associated with increased mortality, independent of body weight.

Authors:  Jennifer E Flythe; Gary C Curhan; Steven M Brunelli
Journal:  Kidney Int       Date:  2012-09-26       Impact factor: 10.612

View more
  8 in total

1.  Incentives and payments in pragmatic clinical trials: Scientific, ethical, and policy considerations.

Authors:  Andrew Garland; Kevin Weinfurt; Jeremy Sugarman
Journal:  Clin Trials       Date:  2021-12       Impact factor: 2.486

2.  Practical steps to identifying the research risk of pragmatic trials.

Authors:  Scott Yh Kim; Jonathan Kimmelman
Journal:  Clin Trials       Date:  2022-03-29       Impact factor: 2.599

3.  Diagnostic accuracy of contrast enhanced ultrasound in patients with blunt abdominal trauma presenting to the emergency department: a systematic review and meta-analysis.

Authors:  Zhongheng Zhang; Yucai Hong; Ning Liu; Yuhao Chen
Journal:  Sci Rep       Date:  2017-06-30       Impact factor: 4.379

4.  Ethical issues in pragmatic trials of "standard-of-care" interventions in learning health care systems.

Authors:  Scott Y H Kim
Journal:  Learn Health Syst       Date:  2018-01-10

5.  The ethical challenges raised in the design and conduct of pragmatic trials: an interview study with key stakeholders.

Authors:  Stuart G Nicholls; Kelly Carroll; Merrick Zwarenstein; Jamie C Brehaut; Charles Weijer; Spencer P Hey; Cory E Goldstein; Ian D Graham; Jeremy M Grimshaw; Joanne E McKenzie; Dean A Fergusson; Monica Taljaard
Journal:  Trials       Date:  2019-12-23       Impact factor: 2.279

6.  Experimenting with modifications to consent forms in comparative effectiveness research: understanding the impact of language about financial implications and key information.

Authors:  Nyiramugisha K Niyibizi; Candace D Speight; Gabriel Najarro; Andrea R Mitchell; Ofer Sadan; Yi-An Ko; Neal W Dickert
Journal:  BMC Med Ethics       Date:  2022-03-27       Impact factor: 2.652

Review 7.  Ethical issues in pragmatic randomized controlled trials: a review of the recent literature identifies gaps in ethical argumentation.

Authors:  Cory E Goldstein; Charles Weijer; Jamie C Brehaut; Dean A Fergusson; Jeremy M Grimshaw; Austin R Horn; Monica Taljaard
Journal:  BMC Med Ethics       Date:  2018-02-27       Impact factor: 2.652

8.  Willingness to participate in pragmatic dialysis trials: the importance of physician decisional autonomy and consent approach.

Authors:  Katherine R Courtright; Scott D Halpern; Steven Joffe; Susan S Ellenberg; Jason Karlawish; Vanessa Madden; Nicole B Gabler; Stephanie Szymanski; Kuldeep N Yadav; Laura M Dember
Journal:  Trials       Date:  2017-10-11       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.